[vc_column col_width=”90″][prkwp_styled_title prk_in=”NEW! Oncology and Biosimilar Sub-Report” align=”Center” font_weight=”700″ text_color=”#ffffff” title_size=”h1″ margin_bottom=”6px” css_animation=”right-to-left” css_delay=”20″ custom_css=”text-shadow: 6px 6px 9px rgb(0, 0, 0), 5px 5px 31px rgb(0, 0, 0);”][prkwp_spacer size=”25″][prkwp_styled_title prk_in=”Add-On To Canadian Reimbursement and Forecasting Timelines (CRaFT)
October 2021 Update” align=”Center” font_weight=”300″ text_color=”#ffffff” title_size=”h4″ margin_bottom=”6px” css_animation=”right-to-left-faster” css_delay=”28″ custom_css=”text-shadow: 6px 6px 9px rgb(0, 0, 0), 5px 5px 31px rgb(0, 0, 0);”][/vc_column]
[vc_column col_width=”80″ css_animation=”hook_fade_waypoint” css_delay=”1300″ bg_color=”#ffffff”][prkwp_spacer size=”80″][vc_column_text]

Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Oncology and Biosimilar Sub-Report offers credible, relevant insights related to oncology (IV vs. oral) and biosimilar files to support a company’s reimbursement forecasting needs.

[/vc_column_text][prkwp_spacer size=”80″][/vc_column]

[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column width=”2/3″ col_width=”70″ css_animation=”hook_fade_waypoint” css_delay=”12″ bg_color=”#f9f9f9″][prkwp_spacer size=”130″][prkwp_service name=”WHY DO YOU NEED THIS SUB-REPORT?” text_color=”#12b2cb” icon_type=”custom_image” align=”center” text_align=”hook_left_align” icon_up_color=”#ffffff” el_class=”text-light”][vc_column_text]

The CRaFT Oncology and Biosimilar Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the oncology and biosimilar public market reimbursement process – from HTA submission to provincial listing.

[/vc_column_text][prkwp_spacer size=”130″][/vc_column][vc_column width=”1/3″ bg_color=”#f9f9f9″][prkwp_spacer size=”80″][vc_column_text css_animation=”hook_fade_waypoint”][/vc_column_text][prkwp_spacer size=”80″][/vc_column]

[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column width=”1/2″ col_width=”90″ css_animation=”hook_fade_waypoint” css_delay=”” bg_image=”6498″][prkwp_spacer size=”120″][vc_column_text]

[/vc_column_text][prkwp_spacer size=”75″][/vc_column][vc_column width=”1/2″ col_width=”65″ bg_color=”#29b9cf”][prkwp_spacer size=”100″][prkwp_service name=”WHAT DOES THE REPORT INCLUDE?” text_color=”#13294b” icon_type=”custom_image” align=”center” text_align=”hook_left_align” icon_up_color=”#ffffff” el_class=”text-light”][prkwp_spacer size=”30″][vc_column_text css_animation=”hook_fade_waypoint”]

This CRaFT Oncology and Biosimilar Sub-Report includes 50+ page of insights on IV and oral oncology drugs related to:

  • CADTH review volume & timeline
  • pCPA volume for initiated, completed, closed, and not-negotiated files
  • pCPA under-consideration and under-negotiation timeline
  • Listing volume & timeline for each province
  • Market access timeline forecasting (from HTA submission to first listing)

It also includes biosimilar metrics related:

  • Oncology & non-oncology
  • Volume of funded biosimilars for each province
  • Average time to list for biosimilars for each province
  • Average time under negotiation for oncology & non-oncology biosimilars

[/vc_column_text][prkwp_spacer size=”45″][/vc_column]

[vc_column][prk_line color="#efefef"][/vc_column]
[vc_column width=”1/2″ col_width=”80″][prkwp_spacer size=”45″][vc_column_text css_animation=”hook_fade_waypoint” custom_css=”margin-right:90px;”][/vc_column_text][prkwp_spacer size=”45″][/vc_column][vc_column width=”1/2″ col_width=”80″][prkwp_spacer size=”45″][vc_column_text]

For further information on the content and pricing of CRaFT and the Oncology and Biosimilar Sub-report, please complete your contact information on our main CRaFT Report page.

[/vc_column_text][prk_wp_theme_button prk_in=”← Back to Main CRaFT Report” link=”https://morseconsulting.ca/canadian-reimbursement-and-forecasting-timelines-report/#craftform”][/vc_column]

Canadian Reimbursement and Forecasting Timelines (CRaFT) - Oncology and Biosimilar Sub-Report, June 2021 Update